Valneva/$VALN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Valneva
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
Ticker
$VALN
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
713
ISIN
US92025Y1038
Website
Valneva Metrics
BasicAdvanced
$463M
-
-$0.62
1.10
-
Price and volume
Market cap
$463M
Beta
1.1
52-week high
$8.20
52-week low
$5.70
Average daily volume
58K
Financial strength
Current ratio
2.703
Quick ratio
1.756
Long term debt to equity
107.697
Total debt to equity
120.481
Interest coverage (TTM)
-6.60%
Profitability
EBITDA (TTM)
-156.531
Gross margin (TTM)
5.74%
Net profit margin (TTM)
-43.21%
Operating margin (TTM)
-81.28%
Effective tax rate (TTM)
-2.85%
Revenue per employee (TTM)
$299,720
Management effectiveness
Return on assets (TTM)
-19.19%
Return on equity (TTM)
-44.11%
Valuation
Price to revenue (TTM)
3.976
Price to book
2.07
Price to tangible book (TTM)
2.41
Price to free cash flow (TTM)
-12.266
Free cash flow yield (TTM)
-8.15%
Free cash flow per share (TTM)
-46.63%
Growth
Revenue change (TTM)
21.64%
Earnings per share change (TTM)
206.84%
3-year revenue growth (CAGR)
-18.74%
10-year revenue growth (CAGR)
12.99%
3-year earnings per share growth (CAGR)
-8.59%
10-year earnings per share growth (CAGR)
12.84%
Bulls say / Bears say
Valneva raised its 2024 product sales guidance to €170-190 million, anticipating growth from its travel vaccines and the launch of IXIARO® (reuters.com)
The company significantly reduced its net loss from €101.4 million in 2023 to €12.2 million in 2024, aided by the sale of a Priority Review Voucher (tipranks.com)
Valneva's Lyme disease vaccine candidate, VLA15, is progressing in Phase 3 trials, with first results expected by the end of 2025, potentially leading to significant future revenues (tipranks.com)
Valneva's total revenues dropped to €153.7 million in 2023 from €361.3 million in 2022, missing analyst estimates of €171.7 million (reuters.com)
The company reported an operating loss of €82.1 million in 2023, though reduced from €113.4 million in 2022, indicating ongoing profitability challenges (valneva.com)
Valneva's debt-to-equity ratio stands at 103.4%, reflecting a high level of debt relative to equity, which may pose financial risks (simplywall.st)
Data summarised monthly by Lightyear AI. Last updated on 11 Jun 2025.
Valneva News
AllArticlesVideos
UK's MHRA suspends Valneva's chikungunya vaccine for elderly
Reuters·2 weeks ago
Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for its Single-Shot Chikungunya Vaccine IXCHIQ®
GlobeNewsWire·2 weeks ago
Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Valneva stock?
Valneva (VALN) has a market cap of $463M as of June 20, 2025.
What is the P/E ratio for Valneva stock?
The price to earnings (P/E) ratio for Valneva (VALN) stock is 0 as of June 20, 2025.
Does Valneva stock pay dividends?
No, Valneva (VALN) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next Valneva dividend payment date?
Valneva (VALN) stock does not pay dividends to its shareholders.
What is the beta indicator for Valneva?
Valneva (VALN) has a beta rating of 1.1. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.